33.42

2.14% 0.70

After Hours: 35.00 1.58 +4.73%

Collegium Pharmaceutical Inc (COLL)

Overview News Price History Option Chain Financials Discussions Forecast

Collegium Pharmaceutical Inc stock is traded at $33.42, with a volume of 339.43K. It is up +2.14% in the last 24 hours and down -20.16% over the past month. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Previous Close:

$32.72

Open:

$32.6

24h Volume:

339.43K

Relative Volume:

0.96

Market Cap:

$1.06B

Revenue:

$566.77M

Net Income/Loss:

$48.16M

P/E Ratio:

-90.32

EPS:

-0.37

Net Cash Flow:

$274.29M

1W Performance:

-5.16%

1M Performance:

-20.16%

6M Performance:

-10.90%

1Y Performance:

+50.54%

1-Day Range:

$32.52

$33.53

1-Week Range:

$32.52

$35.62

52-Week Range:

$21.40

$42.29

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name

Collegium Pharmaceutical Inc

Sector

Healthcare (1182)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

781-713-3699

Address

100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA

Employee

197

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

COLL's Discussions on Twitter

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-24	Downgrade	Jefferies	Buy → Hold
Aug-25-23	Reiterated	Needham	Buy
May-02-23	Resumed	Jefferies	Buy
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Jul-14-20	Initiated	BWS Financial	Sell
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy
Oct-30-19	Reiterated	Needham	Buy
May-03-19	Resumed	H.C. Wainwright	Buy
Apr-12-19	Resumed	Janney	Buy
Mar-20-19	Initiated	SunTrust	Hold
Jan-16-19	Reiterated	Needham	Buy
Mar-08-18	Reiterated	H.C. Wainwright	Buy
Feb-07-18	Reiterated	Needham	Buy
Dec-05-17	Reiterated	Needham	Buy
Sep-11-17	Initiated	H.C. Wainwright	Buy
May-11-17	Reiterated	Needham	Buy
Sep-13-16	Initiated	Gabelli & Co	Buy
Jun-01-15	Initiated	Jefferies	Buy
Jun-01-15	Initiated	Needham	Buy
Jun-01-15	Initiated	Piper Jaffray	Overweight

View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

Nov 04, 2024

Collegium Pharmaceutical is Now Oversold (COLL) - Nasdaq

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Acquires 177,129 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Nov 03, 2024

Nov 02, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Average Target Price from Analysts - Defense World

Nov 02, 2024

Oct 31, 2024

(COLL) Trading Report - Stock Traders Daily

Oct 31, 2024

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 31, 2024

Collegium Pharmaceutical (COLL) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 30, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 30, 2024

Allspring Global Investments Holdings LLC Has $3.08 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Oct 30, 2024

Oct 29, 2024

Assenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Oct 29, 2024

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire

Oct 24, 2024

Oct 23, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com - MarketBeat

Oct 23, 2024

StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy - Defense World

Oct 23, 2024

Oct 22, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2024 Earnings Call Transcript - MSN

Oct 22, 2024

Oct 20, 2024

(COLL) Investment Report - Stock Traders Daily

Oct 20, 2024

Oct 19, 2024

Inspire Investing LLC Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat

Oct 19, 2024

Oct 17, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by StockNews.com - Defense World

Oct 17, 2024

Oct 16, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Down 6.5% in September - MarketBeat

Oct 16, 2024

Sanctuary Advisors LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Oct 16, 2024

Oct 15, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at StockNews.com - MarketBeat

Oct 15, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Receives Neutral Rating from Piper Sandler - Defense World

Oct 15, 2024

Oct 14, 2024

SG Americas Securities LLC Has $707,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World

Oct 14, 2024

Oct 11, 2024

Collegium Pharmaceutical (NASDAQ:COLL) Given "Neutral" Rating at Piper Sandler - MarketBeat

Oct 11, 2024